Fidia Farmaceutici S.p.a.

Anna Maria Zanellato

Giovanni Gennari

Monica Campisi

Davide Bellini

Vincenza Corsa

Devis Galesso

Patrizia Santi

Giancarlo Carpanese

Cristina Padula

Lanfranco Callegaro

Susanna Vaccaro

Mara Pittarello

Laura Pilotto

Antonio Gambillara

The present invention relates to a multilayer composite material for the treatment of wounds and lesions and to a dressing comprising said multilayer material.

Multilayer composite material

The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and/or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.

Pharmaceutical compositions with hydrating and lubricating activity

The present invention relates to pharmaceutical formulations containing a combination of specific high-molecular weight hyaluronic acid derivatives and chondroitin sulfate to be used in the treatment of osteoarthritis, of subchondral damage, osteoporosis, synovitis, tenosynovitis, tendinitis, tendinosis, as an intra-articular washing liquid and as a viscous substitute of synovial fluid following osteochondral surgery. These formulations are also suitable for the treatment of interstitial cystitis.

Pharmaceutical formulations comprising chondroitin sulfate and hyaluronic acid derivatives

The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and antiinflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and antiinflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.

Sulphated hyaluronic acids as regulator agents of the cytokine activity

The present invention relates to a high adhesion dermal therapeutic system comprising an adhesive polymeric matrix with a salt of Diclofenac.

Dermal therapeutic system with high adhesivity

The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.

The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and/or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20&#xb0; C. and at shear rate of D=350 s, comprised between 100 and 250 c Poise and/or a Kinematic viscosity comprised between 99 and 248 cSt (measured at the same conditions); b) a culture of mesenchymal stem cells, and/or c) a platelet-rich hemo-derivative. This type of material in form of viscous liquid is particularly suitable for the therapy of osteoarthrosis, ligament damage, in particular tendon and cartilage damage) and may be administered intra-articularly, intradermally or directly applied in situ without altering the properties of the mesenchymal stem cells and/or platelets contained therein.

Biological material suitable for the therapy of osteoarthrosis, ligament damage and for the treatment of joint disorders

The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs.

Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring

Process for the preparation of phosphatidylserine of formula wherein Rand Rindependently represent a saturated, mono-unsaturated or polyunsaturated acyl C-C, X=OH or OM where M=alkaline or alkaline earth metal, ammonium, alkylammonium (including the inner salt) including the transphosphatidylation reaction between phosphatidylcholine of the general formula wherein Rand Rand X have the above specified meanings, R=CH&#x2014;CH&#x2014;NHo CH&#x2014;CH&#x2014;N(CH)and Serine in D, L or racemic form catalized by the phospholipase D enzyme (PLD),

Process for the preparation and isolation of phosphatides

The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxyl groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs.

Growing community of inventors

Abano Terme, Italy

Anna Maria Zanellato